TickerTalks
Browse all tickers →
TickerTalks›$INO
ININO

Inovio Pharmaceuticals, Inc.

$INO·$79M·Biotechnology·Healthcare
$1.04+5.5%YTD-43.0%1Y-59.1%
Price updated 9h ago·X counts updated 4d ago
ININO
$INOInovio Pharmaceuticals, Inc.
$1.04+5.48%48 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $INO on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

48X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $INO's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 82% of tracked names.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $INO — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Too early to tellStalledAI verdict · as of 2026-10-03

The move has stalled — likely just drifts unless something new shows up.

Inovio sub-$2 and pre-revenue — the pipeline needs a specific milestone to reset the chart.

Inovio Pharmaceuticals is a clinical-stage DNA-vaccine company whose 2026 story has been pipeline-focused — the Wainwright and PYXS comparison coverage suggests the Street still models Inovio as a potential takeout candidate, but current operations don't support a stand-alone thesis.

  • The P&L is pre-revenue: zero quarterly revenue with EPS of -$0.07 and trailing EPS prints beating Street estimates by 67% and 20% on tiny expectations — these aren't surprises that move stock values, these are the kind of noise that happens when revenue is zero.
  • The specific capital-markets setup is thin: the Pyxis Oncology head-to-head and H.C. Wainwright conference appearance are the two visible signals, which combined with the sub-$2 handle imply the market is waiting for either a specific pipeline readout or a strategic transaction.

At 30% of its 52-week range going into Nov 10 earnings, the setup is stalled on pipeline uncertainty. Any specific trial-readout timeline, named partnership, or dilution-adjacent financing is the trigger; another all-conference-attendance quarter without named milestone is the invalidation.

What to watch: Nov 10 Q3 earnings — any specific pipeline milestone, cash runway, named partnership commentary, and dilution direction. Named partnership is the trigger; conference-only cadence is the invalidation.

On the calendar: 2026-11-10 — Q3 earnings

pre revenuepipeline stage

Read the AI verdict on $INO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

DNA medicine biotech developing HPV-related cancer treatments and infectious disease vaccines using electroporation delivery technology.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $INO.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $INO

Neutral — DNA medicine biotech developing HPV-related cancer treatments and infectious disease vaccines using electroporation delivery technology.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-6.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-527%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-10.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-0.07$-0.22+67.7%
Q1 2026May 13, 2026$-0.28$-0.35+20.0%
Q4 2025Mar 12, 2026$0.06$-0.37+116.2%
Q3 2025Nov 10, 2025$-0.87$-0.42-106.3%
Next earningsTue, Nov 10·consensus EPS $-0.20

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.07$-39.6B
Q1 FY26$0-100.0%——$-0.28$-21.6M
Q4 FY25$0-100.0%——$0.05$-19.5M
Q3 FY25$0———$-0.87$-21.6M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$667K$416K – $874K-$0.76-$0.77 – -$0.752
FY27$50.6M$36.7M – $64.5M-$0.43-$0.65 – -$0.202
FY28$79.1M$49.4M – $103.7M-$0.10-$0.14 – -$0.051
FY29$157.3M$98.2M – $206.2M$0.27$0.14 – $0.381
FY30$222.4M$138.9M – $291.5M$0.66$0.34 – $0.931

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.22%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-20.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β1.615-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 27 other (11 awards · 8 exempts · 8 inkinds) in window

See when $INO insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KCharter amendmentOct 68-K — Item 5.03: Charter amendment
8-KMaterial agreementJul 318-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

Inovio Pharmaceuticals, Inc. (INO), the Plymouth Meeting, PA-based DNA medicine biotech, filed an 8-K on July 31, 2026 disclosing entry into an underwriting agreement with Piper Sandler for a public offering of 21,052,632 shares of common stock plus warrants to purchase up to 42,105,264 additional shares at an exercise price of $1.10 per share, at a combined price of $0.95. Net proceeds are expected to be approximately $18.3 million after underwriting discounts and offering expenses. The underwriter exercised its overallotment option with respect to warrants for an additional 6,315,788 shares. The offering was expected to close around July 31, 2026.

424B5Prospectus supplement (offering)Jul 30424B5
AI summary

Inovio Pharmaceuticals, Inc. (INO) filed a 424B5 prospectus supplement on July 30, 2026 for the public offering of 21,052,632 shares of common stock paired with warrants to purchase up to 42,105,264 shares, at a combined price of $0.95 per unit — a discount to the then-market price of $1.03 per share. Total gross proceeds are $20,000,000, with underwriting discounts of approximately $1.2 million paid to Piper Sandler. Warrants carry a $1.10 exercise price, five-year term, and are immediately exercisable. The offering represents substantial dilution given Inovio's prior share count and the scale of warrant coverage at double the share count.

424B5Prospectus supplement (offering)Jul 29424B5
AI summary

Inovio Pharmaceuticals (INO) filed a preliminary 424B5 prospectus supplement on July 29, 2026 to raise capital through a public offering of common stock paired with warrants. Each share comes bundled with a warrant to purchase two additional shares, a highly dilutive 2:1 warrant coverage ratio. The stock last traded at $1.03/share, signaling an offering from financial stress. This capital raise reflects ongoing cash burn as INO funds its clinical-stage DNA medicine pipeline.

S-3Shelf registrationJul 2S-3
AI summary

Inovio Pharmaceuticals (INO) filed an S-3 shelf registration statement on July 2, 2026, establishing a framework for offering securities on a delayed or continuous basis. No offering size, timing, or pricing is specified; the S-3 is preparatory infrastructure enabling future equity or debt capital raises. As a clinical-stage biotech with ongoing cash burn, this shelf should be read alongside the 424B5 prospectus supplement filed later in July that priced an actual dilutive common stock offering.

8-KCharter amendmentMay 208-K — Item 5.03: Charter amendment · Item 5.07: Shareholder vote
+ 14 other (7 13Gs · 3 earnings 8-Ks · 2 10-Qs · 1 EFFECT) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Critical Survey: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)defenseworld.net·15d agoBet on 4 Top-Ranked Stocks With Rising P/Ezacks.com·32d agoInovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcriptseekingalpha.com·35d agoInovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Loomsmarketbeat.com·35d agoInovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRPmarketbeat.com·36d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $INO on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport